Kenyan Health Patient Information Leaflet
Therapeutic agent (verify pharmacological class)
Symptomatic relief of allergic conditions such as allergic rhinitis, conjunctivitis and chronic urticaria; prophylaxis against asthma; chronic asthma associated with allergy. Clinical selection for Levocetirizine / Montelukast should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
Directions adults 65 years of age and older ask a doctor adults and children 12-64 years of age take 1 tablet (5 mg) once daily in the evening do not take more than 1 tablet (5 mg) in 24 hours 1/2 tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms children 6-11 years of age take 1/2 tablet (2.5 mg) once daily in the evening do not take more than 1/2 tablet (2.5 mg) in 24 hours children under 6 years of age do not use consumers with kidney disease do not use
[From component Levocetirizine] Anorexia; increased appetite; taste perversion; dyspepsia; gastritis; stomatitis;enlarged abdomen; eructation; flatulence; constipation; melaena; rectal hemorrhage; hemorrhoids.
Store as labelled. Keep out of reach of children.